Abstract
ABSTRACT
The mammalian immune system has evolved to produce multi-tiered responses consisting of both innate and adaptive immune cells collaborating to elicit a functional response to a pathogen or neoplasm. Immune cells possess a shared ancestry, suggestive of a degree of coevolution that has resulted in optimal functionality as an orchestrated and highly collaborative unit. Therefore, the development of therapeutic modalities that harness the immune system should consider the crosstalk between cells of the innate and adaptive immune systems in order to elicit the most effective response. In this review, the authors will discuss the success achieved using adoptive cellular therapy in the treatment of cancer, recent trends that focus on purified T cells, T cells with genetically modified T-cell receptors and T cells modified to express chimeric antigen receptors, as well as the use of unfractionated immune cell reprogramming to achieve optimal cellular crosstalk upon infusion for adoptive cellular therapy.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1 . Cancer immunoediting and “spontaneous” tumor regression. Pathol. Res. Pract. 206(1), 1–8 (2010).
- 2 . Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 28(1), 89–98 (1971).
- 3 Cancer following renal transplantation. Aust. NZ J. Surg. 49(6), 617–620 (1979).
- 4 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346–2357 (2005).
- 5 T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95), 95ra73 (2011).• Describes the potential of chimeric antigen receptor-modified T cells for the effective treatment of B-cell malignancies.
- 6 Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368(16), 1509–1518 (2013).
- 7 Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126–129 (2006).• Describes the therapeutic potential of genetically engineered cells for the biological therapy of cancer.
- 8 Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3), 535–546 (2009).
- 9 Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15(4), 825–833 (2007).
- 10 . Chimeric antigen receptor-modified T cells: clinical translation in stem cell transplantation and beyond. Biol. Blood Marrow Transplant. 19(1 Suppl), S2–S5 (2013).
- 11 A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12(20 Pt 1), 6106–6115 (2006).
- 12 Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24(13), e20–e22 (2006).
- 13 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).
- 14 Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12(12), 1005–1016 (2005).
- 15 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
- 16 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134–144 (2013).
- 17 The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. J. Transl. Med. 11, 108 (2013).
- 18 The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13), 2286–2294 (2010).
- 19 . PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication. J. Viral Hepat. 20(Suppl. 1), 27–39 (2013).
- 20 . Do the terms innate and adaptive immunity create conceptual barriers? Nat. Rev. Immunol. 9(5), 302–303 (2009).
- 21 . Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol. Immunother. 60(8), 1061–1074 (2011).
- 22 . NKT cells direct monocytes into a DC differentiation pathway. J. Leukoc. Biol. 81(5), 1224–1235 (2007).
- 23 Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19(4), 561–569 (2003).
- 24 . Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J. Immunol. 182(4), 1818–1828 (2009).•• Describes the ability of activated natural killer T cells to convert myeloid-derived suppressor cells into immunogenic dendritic cells.
- 25 . The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int. J. Cancer 131(3), 741–751 (2012).
- 26 . A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233(4770), 1318–1321 (1986).
- 27 Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676–1680 (1988).•• First-in-human study using tumor-infiltrating lymphocytes expanded in IL-2 to treat patients with metastatic melanoma.
- 28 Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550–4557 (2011).
- 29 . Immunology of tumor infiltrating lymphocytes. Ann. Surg. 201(2), 158–163 (1985).
- 30 . Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br. J. Urol. 80(4), 543–547 (1997).
- 31 . Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application. J. Skin Cancer. 2011, 574695 (2011).
- 32 Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 31(17), 2152–2159 (2013).
- 33 Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol. 168(7), 3140–3144 (2002).
- 34 . A subset of CD4+ thymocytes selected by MHC class I molecules. Science 263(5154), 1774–1778 (1994).
- 35 . Total lymphocyte CD8 expression is not a reliable marker of cytotoxic T-cell populations in human peripheral blood following an acute bout of high-intensity exercise. Brain Behav. Immun. 22(3), 375–380 (2008).
- 36 . Differential cell adhesion molecule expression and lymphocyte mobilisation during prolonged aerobic exercise. Eur. J. Appl. Physiol. 84(4), 272–282 (2001).
- 37 High-intensity exercise elicits the mobilization of senescent T lymphocytes into the peripheral blood compartment in human subjects. J. Appl. Physiol. (1985) 103(1), 396–401 (2007).
- 38 Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J. Immunother. 33(8), 840–847 (2010).
- 39 Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer 65(4), 413–421 (1996).
- 40 Tumor infiltrating lymphocytes and continuous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma. Tumori 86(1), 46–52 (2000).
- 41 Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients. Cancer Immunol. Immunother. 46(4), 185–193 (1998).
- 42 . Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer. 3(1), 35–45 (2003).
- 43 . Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86(24), 10024–10028 (1989).
- 44 . Cell transfer immunotherapy for metastatic solid cancer – what clinicians need to know. Nat. Rev. Clin. Oncol. 8(10), 577–585 (2011).
- 45 . CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol. Med. 18(7), 377–384 (2012).
- 46 T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122(18), 3138–3148 (2013).
- 47 Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia doi:10.1038/leu.2014.62 (2014) (Epub ahead of print).
- 48 The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14(10), 1777–1784 (2000).
- 49 . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725–733 (2011).
- 50 B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12), 2709–2720 (2012).
- 51 Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116(20), 4099–4102 (2010).
- 52 . Excitement over CAR-engineered T-cells in leukemia and lymphoma. Medscape (2013). www.medscape.com/viewarticle/817453
- 53 . Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr. Opin. Oncol. 25(6), 701–706 (2013).
- 54 Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk. Lymphoma 55(9), 2085–2092 (2014).
- 55 Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112(6), 2261–2271 (2008).
- 56 CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66(22), 10995–11004 (2006).
- 57 . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18(4), 843–851 (2010).
- 58 Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365(18), 1673–1683 (2011).
- 59 CD28 costimulation Impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing Lck activation. Mol. Ther. 19(4), 760–767 (2011).
- 60 . Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58(1), 49–59 (2009).
- 61 Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 320(6059), 232–238 (1986).
- 62 . Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163(1), 507–513 (1999).
- 63 . High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc. Natl Acad. Sci. USA 92(17), 7739–7743 (1995).
- 64 Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 83(7), 1988–1997 (1994).
- 65 . Retroviral-mediated gene transfer in primary murine and human T-lymphocytes. Mol. Biotechnol. 15(2), 133–142 (2000).
- 66 Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res. 69(24), 9385–9394 (2009).
- 67 T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. Hum. Gene Ther. 20(12), 1576–1588 (2009).
- 68 Comparison of lentiviral and Sleeping Beauty mediated alphabeta T cell receptor gene transfer. PLoS ONE 8(6), e68201 (2013).
- 69 . Challenges in T cell receptor gene therapy. J. Gene Med. 14(6), 386–399 (2012).
- 70 CD3 limits the efficacy of TCR gene therapy in vivo. Blood 118(13), 3528–3537 (2011).
- 71 Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 69(23), 9003–9011 (2009).
- 72 . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer. Cell. 21(3), 309–322 (2012).
- 73 . GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 123(1), 39–49 (2010).
- 74 . Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59(10), 1593–1600 (2010).
- 75 . Myeloid-derived suppressor cells: a double-edged sword? Int. J. Exp. Pathol. 92(2), 73–78 (2011).
- 76 . Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol. Immunother. 58(6), 941–953 (2009).
- 77 Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J. Immunol. 180(12), 7898–7906 (2008).
- 78 . Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68(13), 5439–5449 (2008).
- 79 Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4+ Foxp3+ Treg expansion. Am. J. Transplant. 13(12), 3123–3131 (2013).
- 80 . Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12(4), 253–268 (2012).
- 81 Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J. Immunol. 187(2), 708–717 (2011).
- 82 Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells. Breast Cancer Res. Treat. 142(1), 45–57 (2013).• First-in-human study to demonstrate reprogrammed immune cells contain activated natural killer T cells that can overcome myeloid-derived suppressor cell-mediated suppression
- 83 IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J. Immunol. 181(4), 2446–2454 (2008).
- 84 . NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J. Immunol. 170(5), 2540–2548 (2003).
- 85 NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171(10), 5140–5147 (2003).
- 86 . Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195(3), 327–333 (2002).• Demonstrates for the first time bidirectional crosstalk between natural killer cells and dendritic cells, leading to natural killer cell induction of dendritic cell maturation.
- 87 NK cell-derived interferon-gamma orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 36(6), 1047–1059 (2012).
- 88 Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 110(7), 2484–2493 (2007).
- 89 Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin. Biol. Ther. 5(10), 1303–1315 (2005).
- 90 . IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res. (2013).
- 91 Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin. Cancer Res. 19(7), 1858–1872 (2013).
- 92 . Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol. Immunother. 39(2), 93–99 (1994).
- 93 High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201(2), 241–248 (2005).
- 94 Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 191(4), 625–630 (2000).
- 95 Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. J. Transl. Med. 9, 35 (2011).
- 96 . Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. J. Nucl. Med. 49(1), 59–70 (2006).
- 97 Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br. J. Cancer 94(10), 1478–1484 (2006).
- 98 . T cell stimulation and expansion using anti-CD3/CD28 beads. J. Immunol. Meth. 275(1–2), 251–255 (2003).
- 99 . The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Meth. 128(2), 189–201 (1990).
- 100 Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro. J. Immunother. Emphasis. Tumor. Immunol. 18(3), 147–155 (1995).
- 101 . Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors. Int. J. Immunopharmacol. 12(5), 481–490 (1990).
- 102 . Activation of human T lymphocytes by bryostatin. J. Immunol. 141(10), 3263–3269 (1988).
- 103 PKC-theta exists in an oxidized inactive form in naive human T cells. Eur. J. Immunol. 43(6), 1659–1666 (2013).
- 104 Protein kinase C (PKC) alpha and PKC theta are the major PKC isotypes involved in TCR down-regulation. J. Immunol. 176(12), 7502–7510 (2006).
- 105 . Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395(6697), 82–86 (1998).
- 106 Opposing effects of PKCtheta and WASp on symmetry breaking and relocation of the immunological synapse. Cell 129(4), 773–785 (2007).
- 107 Protein kinase C-theta (PKC-theta) in natural killer cell function and anti-tumor immunity. Front. Immunol. 3, 187 (2012).
- 108 Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin. Cancer Res. 4(3), 611–618 (1998).
- 109 Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl Acad. Sci. USA 102(27), 9571–9576 (2005).• Describes the efficacy of central memory T cells against tumor compared with other T cell subsets.
- 110 . Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens 72(3), 187–194 (2008).
- 111 . IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res. Treat. 122(2), 359–369 (2010).
- 112 . Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared with culture in IL-2. Cancer Immunol. Immunother. 58(10), 1565–1576 (2009).
- 113 IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl Acad. Sci. USA 98(15), 8732–8737 (2001).
- 114 . Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. 195(12), 1523–1532 (2002).
- 115 IL-15 regulates homeostasis and terminal maturation of NKT cells. J. Immunol. 187(12), 6335–6345 (2011).
- 116 . Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol. 3(4), 269–279 (2003).
- 117 . A programmed switch from IL-15- to IL-2-dependent activation in human NK cells. J. Immunol. 182(10), 6267–6277 (2009).
- 118 . Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38(1), 13–25 (2013).
- 119 . Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc. Natl Acad. Sci. USA 82(18), 6281–6285 (1985).
- 120 . Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441(7095), 890–893 (2006).
- 121 . The dual role of IL-2 in the generation and maintenance of CD8+ memory T cells. J. Immunol. 165(6), 3031–3036 (2000).
- 122 Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. 91(1), 123–132 (1993).
- 123 . Interleukin-2 augments natural killer cell activity. Nature 291(5813), 335–338 (1981).
- 124 . Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes. J. Immunol. 184(11), 6043–6052 (2010).
- 125 . IL-2-dependent adaptive control of NK cell homeostasis. J. Exp. Med. 210(6), 1179–1187 (2013).
- 126 IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J. Exp. Med. 210(6), 1167–1178 (2013).
- 127 . Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J. Exp. Med. 210(6), 1153–1165 (2013).
- 128 . IL-2 triggers specific signaling pathways in human NKT cells leading to the production of pro- and anti-inflammatory cytokines. J. Leukoc. Biol. 84(1), 224–233 (2008).
- 129 . IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo. J. Immunol. 186(11), 6329–6337 (2011).
- 130 A dynamic dual role of IL-2 signaling in the two–step differentiation process of adaptive regulatory T cells. J. Immunol. 190(7), 3153–3162 (2013).
- 131 . IL-2 receptor signaling is essential for the development of Klrg1+ terminally differentiated T regulatory cells. J. Immunol. 189(4), 1780–1791 (2012).
- 132 Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J. Transl. Med. 7, 89 (2009).
- 133 . Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33(2), 153–165 (2010).
- 134 . Selective stimulation of T cell subsets with antibody–cytokine immune complexes. Science 311(5769), 1924–1927 (2006).
- 135 . Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8(5), 615–623 (1998).
- 136 . Fas and the art of lymphocyte maintenance. J. Exp. Med. 183(3), 721–724 (1996).
- 137 . Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long–lived memory cells. Nat. Immunol. 4(12), 1191–1198 (2003).
- 138 . IL-7 promotes the transition of CD4 effectors to persistent memory cells. J. Exp. Med. 198(12), 1807–1815 (2003).
- 139 . IL-7 enhances survival of human CD56bright NK cells. J. Immunother. 33(4), 382–390 (2010).
- 140 Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J. Immunol. 174(3), 1213–1221 (2005).
- 141 Innate-like effector differentiation of human invariant NKT cells driven by IL-7. J. Immunol. 180(7), 4415–4424 (2008).
- 142 . IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J. Leukoc. Biol. 57(5), 763–766 (1995).
- 143 . IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells. Immunity 17(5), 537–547 (2002).
- 144 Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc. Natl Acad. Sci. USA 103(24), 9166–9171 (2006).
- 145 . Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells. J. Immunol. 184(12), 6719–6730 (2010).
- 146 . Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8(5), 591–599 (1998).
- 147 Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191(5), 771–780 (2000).
- 148 IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9(5), 669–676 (1998).
- 149 IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J. Exp. Med. 206(1), 25–34 (2009).
- 150 . Different NK cell developmental events require different levels of IL-15 trans-presentation. J. Immunol. 187(3), 1212–1221 (2011).
- 151 . Thymic and peripheral microenvironments differentially mediate development and maturation of iNKT cells by IL-15 transpresentation. Blood 116(14), 2494–2503 (2010).
- 152 Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J. Transl. Med. 11(1), 145 (2013).
- 153 A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res. Treat. 131(3), 871–880 (2012).
- 154 . Different roles of IL-15 from IL-2 in differentiation and activation of human CD3+CD56+ NKT-like cells from cord blood in long term culture. Int. Immunopharmacol. 8(6), 927–934 (2008).
- 155 Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25(2), 268–276 (2013).
- 156 . Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 16(4), 399–403 (2010).
- 157 The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 10, 1 (2012).